Galectin Therapeutics (GALT) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.32% |
| Dec 31, 2025 | -19.22% |
| Sep 30, 2025 | 4.07% |
| Jun 30, 2025 | 4.88% |
| Mar 31, 2025 | 1.71% |
| Dec 31, 2024 | 21.69% |
| Sep 30, 2024 | 4.46% |
| Jun 30, 2024 | 10.75% |
| Mar 31, 2024 | 7.95% |
| Dec 31, 2023 | -38.04% |
| Sep 30, 2023 | 257.75% |
| Jun 30, 2023 | -18.59% |
| Mar 31, 2023 | 148.40% |
| Dec 31, 2022 | 157.63% |
| Sep 30, 2022 | 24.25% |
| Jun 30, 2022 | 19.19% |
| Mar 31, 2022 | 127.76% |
| Dec 31, 2021 | 6.47% |
| Sep 30, 2021 | 9.32% |
| Jun 30, 2021 | 7.64% |
| Mar 31, 2021 | -50.87% |
| Dec 31, 2020 | 51.52% |
| Sep 30, 2020 | -12.45% |
| Jun 30, 2020 | -13.21% |
| Mar 31, 2020 | -14.39% |
| Dec 31, 2019 | -12.32% |
| Sep 30, 2019 | -13.94% |
| Jun 30, 2019 | -9.87% |
| Mar 31, 2019 | 75.14% |
| Dec 31, 2018 | 53.93% |
| Sep 30, 2018 | -77.69% |
| Jun 30, 2018 | 52.84% |
| Mar 31, 2018 | -61.72% |
| Dec 31, 2017 | -60.47% |
| Sep 30, 2017 | -22.43% |
| Jun 30, 2017 | -21.09% |
| Mar 31, 2017 | -50.54% |
| Dec 31, 2016 | 16.92% |
| Sep 30, 2016 | -10.34% |
| Jun 30, 2016 | -21.26% |
| Mar 31, 2016 | 11.46% |
| Dec 31, 2015 | 15.43% |
| Sep 30, 2015 | 14.44% |